Literature DB >> 27822971

Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue?

Rolf Teschke1,2, Gaby Danan3.   

Abstract

INTRODUCTION: Clinicians and practitioners caring for patients with chronic liver disease are often unsure whether drug therapy is a hazard that increases their patient's risk for drug-induced liver injury (DILI). Areas covered: We searched for reports of drug induced liver injury, both idiosyncratic and intrinsic, in patients with chronic liver disease including non-alcoholic and alcoholic liver disease, and cirrhosis. Reports we analyzed include statin treatment in patients with fatty liver, acetaminophen use in alcoholic fatty liver, antituberculous drugs in patients with tuberculosis and viral hepatitis, antiviral medications in hepatitis and antiretroviral medications in HIV/AIDS. The most challenging cases we found are drug therapy in patients with decompensated liver cirrhosis. Expert opinion: We identified many case reports and case series discussing a potential increased risk of DILI in patients with pre-existing liver disease. However, most of these reports were retrospective and ambiguous. With few exceptions, we conclude that drugs seem to be well tolerated by the majority of patients with pre-existing, non-cirrhotic chronic liver diseases. Special care is needed for some therapies, however, including antiviral therapy in chronic hepatitis B and C and in decompensated liver cirrhosis with impaired drug metabolism. Prospective studies are warranted to valid our conclusions.

Entities:  

Keywords:  Drug-induced liver injury (DILI); Roussel Uclaf Causality Assessment Method (RUCAM); alcoholic liver disease; antituberculous drugs; antiviral drugs; chronic liver disease; drug therapy; hepatitis B; hepatitis C; hepatitis E; liver cirrhosis; nonalcoholic fatty liver disease (NAFLD); statins

Mesh:

Year:  2016        PMID: 27822971     DOI: 10.1080/17425255.2017.1252749

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  15 in total

Review 1.  Drug-Induced Liver Injury: Why is the Roussel Uclaf Causality Assessment Method (RUCAM) Still Used 25 Years After Its Launch?

Authors:  Gaby Danan; Rolf Teschke
Journal:  Drug Saf       Date:  2018-08       Impact factor: 5.606

Review 2.  Drug induced liver injury with analysis of alternative causes as confounding variables.

Authors:  Rolf Teschke; Gaby Danan
Journal:  Br J Clin Pharmacol       Date:  2018-05-14       Impact factor: 4.335

3.  Herbal Traditional Chinese Medicine and suspected liver injury: A prospective study.

Authors:  Dieter Melchart; Stefan Hager; Sabine Albrecht; Jingzhang Dai; Wolfgang Weidenhammer; Rolf Teschke
Journal:  World J Hepatol       Date:  2017-10-18

Review 4.  Drug Induced Liver Injury: Can Biomarkers Assist RUCAM in Causality Assessment?

Authors:  Rolf Teschke; Johannes Schulze; Axel Eickhoff; Gaby Danan
Journal:  Int J Mol Sci       Date:  2017-04-11       Impact factor: 5.923

5.  Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK.

Authors:  Aula Abbara; Sarah Chitty; Jennifer K Roe; Rohma Ghani; Simon M Collin; Andrew Ritchie; Onn Min Kon; John Dzvova; Harriet Davidson; Thomas E Edwards; Charlotte Hateley; Matthew Routledge; Jim Buckley; Robert N Davidson; Laurence John
Journal:  BMC Infect Dis       Date:  2017-03-24       Impact factor: 3.090

6.  Gadoxetic acid-enhanced magnetic resonance imaging to predict paritaprevir-induced hyperbilirubinemia during treatment of hepatitis C.

Authors:  Hironao Okubo; Hitoshi Ando; Yushi Sorin; Eisuke Nakadera; Hiroo Fukada; Junichi Morishige; Akihisa Miyazaki; Kenichi Ikejima
Journal:  PLoS One       Date:  2018-04-30       Impact factor: 3.240

7.  Utilization and Impact of Complementary and Alternative Medicines in Symptomatic Autoimmune Hepatitis Patients.

Authors:  Kayla Gelow; Sai Chalasani; Kelsey Green; Craig Lammert
Journal:  Dig Dis Sci       Date:  2021-06-23       Impact factor: 3.487

8.  Methionine and vitamin B-complex ameliorate antitubercular drugs-induced toxicity in exposed patients.

Authors:  Kennedy I Amagon; Olufunsho Awodele; Abidemi J Akindele
Journal:  Pharmacol Res Perspect       Date:  2017-10

9.  Erzhi Pill® Protected Experimental Liver Injury Against Apoptosis via the PI3K/Akt/Raptor/Rictor Pathway.

Authors:  Hai-Mei Zhao; Xiao-Yun Zhang; Xiu-Yun Lu; Song-Ren Yu; Xin Wang; Yong Zou; Zheng-Yun Zuo; Duan-Yong Liu; Bu-Gao Zhou
Journal:  Front Pharmacol       Date:  2018-03-27       Impact factor: 5.810

Review 10.  Is obesity rather than the dietary supplement used for weight reduction the cause of liver injury?

Authors:  Rolf Teschke; Albrecht Wolff; Axel Eickhoff; Gaby Danan
Journal:  JGH Open       Date:  2018-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.